This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Acceleration Of Clinical Program In Amyotrophic Lateral Sclerosis (ALS) Confirms The Proof Of Efficacy Data Obtained In Animals

PARIS, Nov. 6, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4 th, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.

Two different animal experiments were conducted by Dr. Luis Barbeito from the Institut Pasteur de Montevideo (Uruguay) and by Dr. Patricia Cassina from the Facultad de Medicina, Universidad de la República, Montevideo.

One experiment was aimed at evaluation the effect of masitinib in mice models of ALS (SOD1G93A female mice). Treatment started at 90 days-old animals before symptoms onset and continued until complete paralysis. Assessments were performed at 12 weeks (baseline) and weekly until end stage of paralysis (18-20 weeks). Administration of masitinib significantly delayed age of symptoms onset, improved grip strength and weight loss compared to control animals.

Other experiment was aimed at evaluating the effect of masitinib in a transgenic rat model of ALS (SOD1G93A rats). These rats develop a motor syndrome with symptoms and pathological features of the human disease. Animals were observed weekly for onset of disease symptoms, as well as disease progression to death during 12 weeks of treatment. Compared to control, masitinib prolonged the survival of ALS rats, delaying the progression of paralytic symptoms and weight loss, suggesting a protective effect of masitinib in motor neuron diseases.

Dr Luis Barbeito explained "Because masitinib can modulate inflammation, there is a scientific rationale to evaluate masitinib in the treatment of ALS. The results from the preclinical experiments are encouraging considering that there is no treatment available to ALS other than riluzole which delays death only few months in humans. Preliminary data indicate that masitinib target glial cells that promote ALS progression. Thus, the positive results showed in the mouse and rat trials raise the possibility that masitinib might offer therapeutic benefits in ALS patients, slowing disease progression".

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs